Literature DB >> 7606373

The use of cryopreserved human skin allografts in wound healing following Mohs surgery.

S A Kolenik1, D J Leffell.   

Abstract

BACKGROUND: Immediate reconstruction has become the preferred approach to management of full-thickness cutaneous defects following microscopically controlled excision (MCE) of tumors. In a minority of patients, however, large reconstructive procedures are contraindicated, and a long-term biological dressing that stimulates healing while minimizing wound care is desirable.
OBJECTIVE: To assess the utility of cryopreserved human skin allografts (HSA) in wound care and wound healing following Mohs surgery.
METHODS: Sixteen patients were treated with HSA following MCE and followed postoperatively for evidence of infection, involution, or survival of HSA, and granulation tissue production. Follow-up was 2-26 months.
RESULTS: The use of HSA resulted in one of three general outcomes: rapid healing and rejection, subsequent full-thickness skin grafting, or persistence of HSA during prolonged healing.
CONCLUSIONS: HSA are a safe alternative to immediate reconstruction in a carefully selected population of skin cancer patients. They minimize wound care while providing continuous wound coverage during healing, and are an efficient bridge to full-thickness skin grafting.

Entities:  

Mesh:

Year:  1995        PMID: 7606373     DOI: 10.1111/j.1524-4725.1995.tb00517.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

Review 1.  Skin substitutes for the management of mohs micrographic surgery wounds: a systematic review.

Authors:  Kimberly W Lu; Amor Khachemoune
Journal:  Arch Dermatol Res       Date:  2022-02-15       Impact factor: 3.017

2.  Treatment of third-degree burn wounds in animal specimens: acellular dermis or partial-thickness skin graft.

Authors:  M J Fatemi; M Momeni; A Tavakoli; T Bagheri; A Hosseini; S Araghi; F Ranjpoor; A Zavareh
Journal:  Ann Burns Fire Disasters       Date:  2018-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.